Smoking Increases Risk of Side Effects, Recurrence in Prostate Cancer
the Cancer Therapy Advisor take:
Smoking increases risks for side effects and recurrence in patients being treated for prostate cancer, according to a study published in BJU International.
Michael Zelefsky, MD, and colleagues at the Memorial Sloan Kettering Cancer Center in New York City examined 2,358 patients with prostate cancer who underwent external-beam radiotherapy (EBRT) between 1988 and 2005. They classified patients as never smokers, current smokers, former smokers, or current smoking unknown.
They found that with a median follow-up of about 8 years, current smokers were at a 40 percent increased risk of prostate cancer relapse, along with a two-times increased risk of cancer spread and cancer-related death, compared to never smokers.
Additionally, current and former smokers had a higher likelihood of experiencing side effects such as urinary toxicity that are related to radiotherapy.
“Our findings point to the importance of physicians counseling their patients regarding the potential harms of smoking interfering with the efficacy of therapies ad for increased risks of side effects,” Dr. Zelefsky noted.
Smoking increases risks for side effects and recurrence in patients being treated for prostate cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Pancreatitis and the Risk of Cancer
- RAMIE May Improve Post-operative Outcomes Among Patients With Esophageal Cancer
- Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery Prolongs OS in Gastric Cancer
- Renal Cell Carcinoma: Cost of Treatment May Negate Impact of Treatment Advances
- Pembrolizumab May Be Effective for Previously Treated Hepatocellular Carcinoma
- CTC Screening May Be Effective Method for Preventing Colorectal Cancer
- Physical Activity Intervention May Improve Functional Well-being Among CRC Survivors
- Atezolizumab With Cobimetinib Yields Partial Response in Small Number of Patients With CRC
- Nivolumab May Improve Long-term Complete Response Rate in Subset of Patients With mCRC
- Alcohol Consumption and Cancer